Turkiye Klinikleri Journal of Medical Sciences

.: ORIGINAL RESEARCH
Santral GLP-1'in Gastrik Mukozal Kan Akımına Etkisi; Spesifik Reseptörlerin Rolü
Effect of Central GLP-1 on Gestric Mucosal Blood Flow; the Role of Specific Receptors
Türkan ÇELİKa, Naciye İŞBİLb
aFiziksel Tıp ve Rehabilitasyon Kliniği, Sağlık Bilimleri Üniversitesi Bursa Yüksek İhtisas Eğitim ve Araştırma Hastanesi,
bFizyoloji ABD, Bursa Uludağ Üniversitesi Tıp Fakültesi, Bursa, TÜRKİYE
Turkiye Klinikleri J Med Sci. 2019;39(4):414-21
doi: 10.5336/medsci.2019-66494
Article Language: TR
Full Text
ÖZET
 Amaç: İntraserebroventriküler (ICV) olarak enjekte edilen 'glucagon like peptid-1 (GLP-1)'in sıçanlarda gastrik mukozal kan akımı [gastric mucosal blood flow (GMBF)]'na etkisi, bu etkide santral spesifik reseptörlerinin rolü ve ayrıca absolu etanolün GMBF'de neden olduğu değişikliklerin üzerindeki etkisinin araştırılmasıdır. Gereç ve Yöntemler: ICV enjeksiyonlar için izofloran (%4) anestezisi altında sıçanların kafatasına orta hattın 1,5 mm sağ yanında ve bregmanın 1-1,5 mm arkasında olacak şekilde bir delik açıldı. Bu delikten sağ lateral ventriküle, dik olarak ve alt ucu kafatası yüzeyinden 4,2-4,5 mm kadar derinliğe inecek şekilde 10 mm uzunluğunda bir kanül yerleştirildi. GMBF 'Laser Doppler flowmetre' ile ölçülerek, veriler 'MP30 Data Acquisition System' aracılığıyla bilgisayara aktarıldı. Ölçümler için anestezi altındaki sıçanlarda mide hazırlandıktan sonra mide mukozasına prob yerleştirilerek kalibrasyon için 30 dk beklendi ve bazal kan akımı ölçümleri kaydedildi. GLP-1'in GMBF'deki etkisini araştırmak amacıyla, GLP-1 (3, 10 ve 30 μg/10 μL; ICV) veya serum fizyolojik (10 μL; ICV) enjekte edildi. Spesifik reseptör antagonisti exendin-(9-39) (1 μg/10 μL; ICV) enjekte edildikten 5 dk sonra 10 μg GLP- 1 enjekte edildi. Enjeksiyonları takiben gastrik çember içine serum fizyolojik (1,5 mL) uygulandı ve 30 dak süresince her 5 dk'da gastrik kan akımı kaydedildi. Absolu etanolün GMBF'de neden olduğu değişikler üzerinde GLP-1'in etkisini araştırmak için sıçanlara 10 μg GLP-1 enjeksiyonundan 5 dk sonra gastrik çember içine etanol (1,5 mL) uygulandı. Bulgular: 10 μg ICV GLP-1 GMBF'yi arttırdı ve ICV eksendin- (9-39) bu etkiyi antagonize etti. Ayrıca GLP-1 absolu etanolün GMBF'de oluşturduğu inhibisyonu azalttı. 3 ve 30 μg GLP-1 ise GMBF'yi azalttı. Sonuç: ICV olarak enjekte edilen 10 μg GLP-1'in GMBF'yi artırdığı ve bu etkide, santral spesifik reseptörlerinin rolü olduğu düşünülmektedir. Aynı zamanda santral GLP-1'in GMBF'deki etanol nedenli inhibisyonu önleyebildiği gözlenmiştir. Diğer dozlar ise GMBF'de azalmaya neden olmuştur.

Anahtar Kelimeler: Glukagon benzeri peptid-1; gastrik mukoza; eksendin-(9-39)
ABSTRACT
 Objective: The aim of this study was to investigate the effects of intracerebroventricularly (ICV) injected glucagon like peptide-1 (GLP-1) on gastric mucosal blood flow (GMBF) in rats and the role of central-specific receptors in this effect, and the changes on GMBF induced by intragastric absolute ethanol. Material and Methods: Each animal was anaesthetized with isoflurane (4%) for ICV injections and to drill a burr hole through the skull that is 1.5 mm lateral to the midline and 1-1.5 mm posterior to bregma on the right side. Through this hole, a stainless steel hypodermic cannula of 10 mm length was placed perpendicular to the right lateral ventricle and was lowered 4.2-4.5 mm below the surface of the skull. GMBF was measured by laser Doppler flowmeter, and the data collected by computer using 'MP30 Data Acquisition' System. After preparation of the stomach for GMBF recording, a probe was placed in the gastric mucosa and basal GMBF recordings were obtained after 30-minute stabilization period. Rats were treated with GLP-1 (3, 10 and 30 μg/10 μL; ICV) or saline (10 μL; ICV) to find out the effective dose of ICV GLP-1 on GMBF. Then specific receptor antagonist exendin- (9-39) (1 μg/10 μL; ICV) was injected before the effective dose of ICV GLP-1. Subsequent to those injections serum physiologic were introduced into the gastric chamber and GMBF was recorded every fifth minute during the next 30 min. In order to confirm the effect of GLP-1 on intraluminal absolute-ethanol-induced changes in GMBF, ethanol (1.5 mL) was administrated into the gastric chamber of rats after 5 min of GLP-1 injection. Results: 10 μg ICV GLP-1 increased the GMBF and ICV exendin- (9-39) antagonized this effect. In addition, GLP-1 reduced the inhibition of absolute ethanol on GMBF. Conclusion: We suggest that, ICV GLP-1 increases GMBF and central specific receptors intermediate this effect. At the same time, it is observed that ICV GLP-1 reduced the intraluminal ethanol-induced inhibition of GMBF.

Keywords: Glucagon-like peptide 1; gastric mucosa; exendin-(9-39)
REFERENCES:
  1. Larsen PJ, Holst JJ. Glucagon-related peptide 1 (GLP-1): hormone and neurotransmitter. Regul Pept. 2005;128(2):97-107. [Crossref]  [PubMed] 
  2. Kieffer TJ, Habener JF. The glucagon-like peptides. Endocr Rev. 1999;20(6):876-913. [Crossref]  [PubMed] 
  3. Larsen PJ, Tang-Christensen MM, Holst JJ, Orskov C. Distribution of glucagon-like peptide-1 and other preproglucagon-derived peptides in the rat hypothalamus and brainstem. Neurosci. 1997;77(1):257-70. [Crossref] 
  4. Goke R, Larsen PJ, Mikkelsen JD, Sheikh SP. Distribution of GLP-1 binding sites in the rat brain: evidence that exendin-4 is a ligand of brain GLP-1 binding sites. Eur J Neurosci. 1995;7(11):2294-300. [Crossref]  [PubMed] 
  5. Shimizu I, Hirota M, Ohboshi C, Shima K. Identification and localization of glucagon-like peptide-1 and its receptor in rat brain. Endocrinology. 1987;121(3):1076-82. [Crossref]  [PubMed] 
  6. Schirra J, Sturm K, Leicht P, Arnold R, Goke B, Katschinski M. Exendin (9-39) amide is an antagonist of glucagon-like peptide-1 (7-36)amide in humans. J Clin Invest. 1998;101(7):1421-30. [Crossref]  [PubMed]  [PMC] 
  7. Barragan JM, Eng J, Rodriguez R, Blazquez E. Neural contribution to the effect of glucagon-like peptide-1-(7-36) amide on arterial blood pressure in rats. Am J Physiol. 1999;277(40):E784-91. [Crossref]  [PubMed] 
  8. Eng J, Kleiman WA, Singh L, Singh G, Raufman JP. Isolation and characterization of exendin-4, and exendin-3 analogue, from Heloderma suspectum venom. Further evidence for an exendin receptor on dispersed acini from guinea pig pancreas. J Biol Chem. 1992;267(11):7402-5.
  9. Barragan JM, Rodriguez RE, Eng J, Blazquez E. Interaction of exendin-(9-39) with the effects of glucagon-like peptide-1-(7-36) amide and of exendin-4 on arterial blood pressure and heart rate in rats. Regul Pept. 1996;67(1):63-8. [Crossref] 
  10. Goke R, Fehmann HC, Linn T, Schmidt H, Krause M, Eng J, et al. Exendin-4 is a high potency agonist and truncated exendin-(9-39)-amide an antagonist at the glucagon-like peptide-1-(7-36)-amide receptor of insulin-secreting b-cells. J Biol Chem. 1993;268(26):19650-5.
  11. Wettergren A, Wojdemann M, Meisner S, Stadil F, Host JJ. The inhibitory effect of glucagon-like peptide-1 (GLP-1)7-36 amide on gastric acid secretion in humans depends on an intact vagal innervation. Gut. 1997;40(5):597-601. [Crossref]  [PubMed]  [PMC] 
  12. Imeryuz N, Yegen BC, Bozkurt A, Coskun T, Villanueva-Pe-acarrillo ML, Ulusoy NB. Glucagon-like peptide-1 inhibits gastric emptying via vagal afferent-mediated central mechanisms. Am J Physiol. 1997;273(4 Pt 1):G920-7. [Crossref]  [PubMed] 
  13. Shousha S, Nakahara K, Nasu T, Sakamoto T, Murakami N. Effect of glucagon-like peptide-1 and -2 on regulation of food intake, body temperature and locomotor activity in the Japanese quail. Neurosci Lett. 2007;415(2):102-7. [Crossref]  [PubMed] 
  14. Nerup N, Ambrus R, Lindhe J, Achiam MP, Jeppesen PB, Svendsen LB. The effect of glucagon-like peptide-1 and glucagon-like peptide-2 on microcirculation: a systematic review. Microcirculation. 2017. https://doi.org/10.1111/micc.12367. [Crossref]  [PubMed] 
  15. Isbil-Buyukcoskun N, Gulec G. Effects of intracerebroventricularly injected glucagon-like peptide-1 on cardiovascular parameters; role of central cholinergic system and vasopressin. Regul Pept. 2004;118(1-2):33-8. [Crossref]  [PubMed] 
  16. Nikolaidis LA, Mankad S, Sokos GG, Miske G, Shah A, Elahi D, et al. Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion. Circulation. 2004;109(8):962-5. [Crossref]  [PubMed] 
  17. Sonne DP, Engstrom T, Treiman M. Protective effects of GLP-1 analogues exendin-4 and GLP-1(9-39) amide against ischemia-reperfusion injury in rat heart. Regul Pept. 2008;146(1-3):243-9. [Crossref]  [PubMed] 
  18. Nystrom T, Gonon AT, Sjoholm A, Pernow J. Glucagon-like peptide-1 relaxes rat conduit arteries via an endothelium-independent mechanism. Regul Pept. 2005;125(1-3):173-7. [Crossref]  [PubMed] 
  19. Golpon HA, Puechner A, Welte T, Wichert PV, Feddersen CO. Vasorelaxant effect of glucagon-like peptide-(7-36) amide and amylin on the pulmonary circulation of the rat. Regul Pept. 2001;102(2-3):81-6. [Crossref] 
  20. Basu A, Charkoudian N, Schrage W, Rizza RA, Basu R, Joyner MJ. Beneficial effects of GLP-1 on endothelial function in humans: dampening by glyburide but not by glimepiride. Am J Physiol Endocrinol Metab. 2007;293(5):E1289-95. [Crossref]  [PubMed] 
  21. Isbil-Buyukcoskun N, Cam-Etoz B, Gulec G, Ozluk K. Effect of peripherally-injected glucagon-like peptide-1 on gastric mucosal blood flow. Regul Pept. 2009;157(1-3):72-5. [Crossref]  [PubMed] 
  22. Mersereau WA, Hinchey EJ. Effect of gastric acidity on gastric ulceration induced by hemorrhage in the rat, utilizing a gastric chamber technique. Gastroenterology. 1973;64(6):1130-5. [Crossref] 
  23. Kagstrom J, Olsson C, Axelsson M, Franklin CE. Peptidergic control of gastrointestinal blood flow in the estuarine crocodile, Crocodylus porosus. Am J Physiol. 1998;274(6):R1740-50. [Crossref]  [PubMed] 
  24. Holzer P, Guth PH. Neuropeptide control of rat gastric mucosal blood flow. Increase by calcitonin gene-related peptide and vasoactive intestinal polypeptide, but not substance P and neurokinin A. Circ Res. 1991;68(1):100-5. [Crossref]  [PubMed] 
  25. Ancha H, Ojeas H, Tedesco D, Ward A, Harty RF. Somatostatin-induced gastric protection against ethanol: involvement of nitric oxide and effects on gastric mucosal blood flow. Regul Pept. 2003;110(2):107-13. [Crossref] 
  26. Sibilia V, Rindi G, Pagani F, Rapetti D, Locatelli V, Torsello A, et al. Ghrelin protects against ethanol-induced gastric ulcers in rats: studies on the mechanisms of action. Endocrinology. 2003;144(1):353-9. [Crossref]  [PubMed] 
  27. Clementi G, Caruso A, Cutuli VM, Mangano NG, Salomone S, Lempereur L, et al. Gastroprotective effect of adrenomedullin administered subcutaneously in the rat. Peptides. 2002;23(6):1149-53. [Crossref] 
  28. Isbil-Buyukcoskun N, Gulec G. Investigation of the mechanisms involved in the central effects of glucagon-like peptide-1 on ethanol-induced gastric mucosal lesions. Regul Pept. 2005;128(1):57-62. [Crossref]  [PubMed] 
  29. Isbil-Buyukcoskun N, Gulec G, Cam-Etoz B, Ozluk K. Peripheral GLP-1 gastroprotection against ethanol: the role of exendin, NO, CGRP, prostaglandins and blood flow. Regul Pept. 2009;152(1-3):22-7. [Crossref]  [PubMed] 
  30. Isbil-Buyukcoskun N, Gulec G, Ozluk K. Protective effect of centrally-injected glucagon-like peptide-1 on reserpine-induced gastric mucosal lesions in rat: possible mechanisms. Turk J Gastroenterol. 2006;17(1):1-6.
  31. Isbil-Buyukcoskun N, Gulec G, Cam-Etoz B, Ozluk K. Central effects of glucagon-like peptide-1 on cold-restraint stress-induced gastric mucosal lesions. Turk J Gastroenterol. 2007;18(3):150-6.
  32. Isbil-Buyukcoskun N, Gulec G. Effects of centrally injected GLP-1 in various experimental models of gastric mucosal damage. Peptides. 2004;25(7):1179-83. [Crossref]  [PubMed] 
  33. Pliska V. Models to explain dose-response relationships that exhibit a downturn phase. Trends Pharmacol Sci. 1994;15(6):178-81. [Crossref] 
  34. Guidobono F, Coluzzi M, Pagani F, Pecile A, Netti C. Amylin given by central and peripheral routes inhibits acid gastric secretion. Peptides. 1994;15(4):699-702. [Crossref] 
  35. Clementi G, Amico-Roxas M, Caruso A, Cutuli VM, Maugeri S, Prato A. Protective effects of calcitonin gene-related peptide in different experimental models of gastric ulcers. Eur J Pharmacol. 1993;238(1):101-4. [Crossref] 
  36. Rovati GE, Nicosia S. Lower efficacy: interaction with an inhibitory receptor or partial agonism? Trends Pharmacol Sci. 1994;15(5):140-4. [Crossref] 
  37. Eissele R, Bothe-Sandfort E, Goke B, Eng J, Arnold R, Koop H. Rat gastric somatostatin and gastrin release: interaction of exendin-4 and truncated glucagon-like peptide-1 (GLP-1) amide. Life Sci. 1994;55(8):629-34. [Crossref] 
  38. Guth PH, Paulsen G, Nagata H. Histologic and microcirculatory changes in alcohol-induced gastric lesions in the rat: effect of prostaglandin cytoprotection. Gastroenterology. 1984;87(5):1083-90.
  39. Trier JS, Szabo S, Allan CH. Ethanol-induced damage to mucosal capillaries of rat stomach. Ultrastructural features and effects of prostaglandin F2 beta and cysteamine. Gastroenterology. 1987;92(1):13-22. [Crossref] 
  40. Abdel-Salam OM, Czimmer J, Debreceni A, Szolcsanyi J, Mozsik G. Gastric mucosal integrity: gastric mucosal blood flow and microcirculation. An overview. J Physiol Paris. 2001;95(1-6):105-27. [Crossref] 

.: Up To Date

.: Process List

Login

 Forgot your password?

 New Registration  

Contact

Ortadoğu Reklam Tanıtım Yayıncılık Turizm Eğitim İnşaat Sanayi ve Ticaret A.Ş.

.: Address

Turkocagi Caddesi No:30 06520 Balgat / ANKARA
Phone: +90 312 286 56 56
Fax: +90 312 220 04 70
E-mail: info@turkiyeklinikleri.com

.: Manuscript Editing Department

Phone: +90 312 286 56 56/ 2
E-mail: yaziisleri@turkiyeklinikleri.com

.: English Language Redaction

Phone: +90 312 286 56 56/ 145
E-mail: tkyayindestek@turkiyeklinikleri.com

.: Marketing Sales-Project Department

Phone: +90 312 286 56 56/ 142
E-mail: reklam@turkiyeklinikleri.com

.: Subscription and Public Relations Department

Phone: +90 312 286 56 56/ 118
E-mail: abone@turkiyeklinikleri.com

.: Customer Services

Phone: +90 312 286 56 56/ 118
E-mail: satisdestek@turkiyeklinikleri.com

1. TERMS OF USE

1.1. To use the web pages with http://www.turkiyeklinikleri.com domain name or the websites reached through the sub domain names attached to the domain name (They will be collectively referred as "SITE"), please read the conditions below. If you do not accept these terms, please cease to use the "SITE." "SITE" owner reserves the right to change the information on the website, forms, contents, the "SITE," "SITE" terms of use anytime they want.

1.2. The owner of the "SITE" is Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. (From now on it is going to be referred as "Turkiye Klinikleri", shortly) and it resides at Turkocagi cad. No:30, 06520 Balgat Ankara. The services in the "SITE" are provided by "Turkiye Klinikleri."

1.3. Anyone accessing the "SITE" with or without a fee whether they are a natural person or a legal identity is considered to agree these terms of use. In this contract hereby, "Turkiye Klinikleri" may change the stated terms anytime. These changes will be published in the "SITE" periodically and they will be valid when they are published. Any natural person or legal identity benefiting from and reaching to the "SITE" are considered to be agreed to any change on hereby contract terms done by "Turkiye Klinikleri."

1.4. The "Terms of Use" hereby is published in the website with the last change on March 30th 2014 and the "SITE" is activated by enabling the access to everyone. The "Terms of Use" hereby is also a part of the any "USER Contract" was and/or will be done with the users using "Turkiye Klinikleri" services with or without a fee an inseparable.

2. DEFINITIONS

2.1. "SITE": A website offering different kind of services and context with a certain frame determined by "Turkiye Klinikleri" and it is accessible on-line on http://www.turkiyeklinikleri.com domain name and/or subdomains connected to the domain name.

2.2. USER: A natural person or a legal identity accessing to the "SITE" through online settings.

2.3. LINK: A link enabling to access to another website through the "SITE", the files, the context or through another website to the "SITE", the files and the context.

2.4. CONTEXT: Any visual, literary and auditory images published in the "Turkiye Klinikleri", "SITE" and/or any website or any accessible information, file, picture, number/figures, price, etc.

2.5. "USER CONTRACT": An electronically signed contract between a natural or a legal identity benefiting from special services "Turkiye Klinikleri" will provide and "Turkiye Klinikleri".

3. SCOPE OF THE SERVICES

3.1. "Turkiye Klinikleri" is completely free to determine the scope and quality of the services via the "SITE".

3.2. To benefit the services of "Turkiye Klinikleri" "SITE", the "USER" must deliver the features that will be specified by "Turkiye Klinikleri". "Turkiye Klinikleri" may change this necessity any time single-sided.

3.3. Not for a limited number, the services "Turkiye Klinikleri" will provide through the "SITE" for a certain price or for free are;

- Providing scientific articles, books and informative publications for health industry.

- Providing structural, statistical and editorial support to article preparation stage for scientific journals.

4. GENERAL PROVISIONS

4.1. "Turkiye Klinikleri" is completely free to determine which of the services and contents provided in the "SITE" will be charged.

4.2. People benefiting from the services provided by "Turkiye Klinikleri" and using the website can use the "SITE" only according to the law and only for personal reasons. Users have the criminal and civil liability for every process and action they take in the "SITE". Every USER agrees, declares and undertakes that they will not proceed by any function or action infringement of rights of "Turkiye Klinikleri"s and/or other third parties', they are the exclusive right holder on usage, processing, storage, made public and revealing any written, visual or auditory information reported to Turkiye Klinikleri" and/or "SITE" to the third parties. "USER" agrees and undertakes that s/he will not duplicate, copy, distribute, process, the pictures, text, visual and auditory images, video clips, files, databases, catalogs and lists within the "SITE", s/he will not be using these actions or with other ways to compete with "Turkiye Klinikleri", directly or indirectly.

4.3. The services provided and the context published within the "SITE" by third parties is not under the responsibility of "Turkiye Klinikleri", institutions collaborated with "Turkiye Klinikleri", "Turkiye Klinikleri" employee and directors, "Turkiye Klinikleri" authorized salespeople. Commitment to accuracy and legality of the published information, context, visual and auditory images provided by any third party are under the full responsibility of the third party. "Turkiye Klinikleri" does not promise and guarantee the safety, accuracy and legality of the services and context provided by a third party.

4.4. "USER"s cannot act against "Turkiye Klinikleri", other "USER"s and third parties by using the "SITE". "Turkiye Klinikleri" has no direct and/or indirect responsibility for any damage a third party suffered or will suffer regarding "USER"s actions on the "SITE" against the rules of the hereby "Terms of Use" and the law.

4.5. "USER"s accept and undertake that the information and context they provided to the "SITE" are accurate and legal. "Turkiye Klinikleri" is not liable and responsible for promising and guaranteeing the verification of the information and context transmitted to "Turkiye Klinikleri" by the "USER"s, or uploaded, changed and provided through the "SITE" by them and whether these information are safe, accurate and legal.

4.6. "USER"s agree and undertake that they will not perform any action leading to unfair competition, weakening the personal and commercial credit of "Turkiye Klinikleri" and a third party,  encroaching and attacking on personal rights within the "SITE" in accordance with the Turkish Commercial Code Law.

4.7. "Turkiye Klinikleri" reserves the right to change the services and the context within the "SITE"  anytime. "Turkiye Klinikleri" may use this right without any notification and timelessly. "USER"s have to make the changes and/or corrections "Turkiye Klinikleri" required immediately. Any changes and/or corrections that are required by "Turkiye Klinikleri", may be made by "Turkiye Klinikleri" when needed. Any harm, criminal and civil liability resulted or will result from changes and/or corrections required by "Turkiye Klinikleri" and were not made on time by the "USER"s belongs completely to the users.

4.8. "Turkiye Klinikleri" may give links through the "SITE" to other websites and/or "CONTEXT"s and/or folders that are outside of their control and owned and run by third parties. These links are provided for ease of reference only and do not hold qualification for support the respective web SITE or the admin or declaration or guarantee for the information inside. "Turkiye Klinikleri" does not hold any responsibility over the web-sites connected through the links on the "SITE", folders and context, the services or products on the websites provided through these links or their context.

4.9. "Turkiye Klinikleri" may use the information provided to them by the "USERS" through the "SITE" in line with the terms of the "PRIVACY POLICY" and "USER CONTRACT". It may process the information or classify and save them on a database. "Turkiye Klinikleri" may also use the USER's or visitor's identity, address, e-mail address, phone number, IP number, which sections of the "SITE" they visited, domain type, browser type, date and time information to provide statistical evaluation and customized services.

5. PROPRIETARY RIGHTS

5.1. The information accessed through this "SITE" or provided by the users legally and all the elements (including but not limited to design, text, image, html code and other codes) of the "SITE" (all of them will be called as studies tied to "Turkiye Klinikleri"s copyrights) belongs to "Turkiye Klinikleri". Users do not have the right to resell, process, share, distribute, display or give someone permission to access or to use the "Turkiye Klinikleri" services, "Turkiye Klinikleri" information and the products under copyright protection by "Turkiye Klinikleri". Within hereby "Terms of Use" unless explicitly permitted by "Turkiye Klinikleri" nobody can reproduce, process, distribute or produce or prepare any study from those under "Turkiye Klinikleri" copyright protection.

5.2. Within hereby "Terms of Use", "Turkiye Klinikleri" reserves the rights for "Turkiye Klinikleri" services, "Turkiye Klinikleri" information, the products associated with "Turkiye Klinikleri" copyrights, "Turkiye Klinikleri" trademarks, "Turkiye Klinikleri" trade looks or its all rights for other entity and information it has through this website unless it is explicitly authorized by "Turkiye Klinikleri".

6. CHANGES IN THE TERMS OF USE

"Turkiye Klinikleri" in its sole discretion may change the hereby "Terms of Use" anytime announcing within the "SITE". The changed terms of the hereby "Terms of Use" will become valid when they are announced. Hereby "Terms of Use" cannot be changed by unilateral declarations of users.

7. FORCE MAJEURE

"Turkiye Klinikleri" is not responsible for executing late or never of this hereby "Terms of Use", privacy policy and "USER Contract" in any situation legally taken into account as force majeure. Being late or failure of performance or non-defaulting of this and similar cases like this will not be the case from the viewpoint of "Turkiye Klinikleri", and "Turkiye Klinikleri" will not have any damage liability for these situations. "Force majeure" term will be regarded as outside of the concerned party's reasonable control and any situation that "Turkiye Klinikleri" cannot prevent even though it shows due diligence. Also, force majeure situations include but not limited to natural disasters, rebellion, war, strike, communication problems, infrastructure and internet failure, power cut and bad weather conditions.

8. LAW AND AUTHORISATION TO FOLLOW

Turkish Law will be applied in practicing, interpreting the hereby "Terms of Use" and managing the emerging legal relationships within this "Terms of Use" in case of finding element of foreignness, except for the rules of Turkish conflict of laws. Ankara Courts and Enforcement Offices are entitled in any controversy happened or may happen due to hereby contract.

9. CLOSING AND AGREEMENT

Hereby "Terms of Use" come into force when announced in the "SITE" by "Turkiye Klinikleri". The users are regarded to agree to hereby contract terms by using the "SITE". "Turkiye Klinikleri" may change the contract terms and the changes will be come into force by specifying the version number and the date of change on time it is published in the "SITE".

 

30.03.2014

Privacy Policy

We recommend you to read the terms of use below before you visit our website. In case you agree these terms, following our rules will be to your favor. Please read our Terms of Use thoroughly.

www.turkiyeklinikleri.com website belongs to Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. and is designed in order to inform physicians in the field of health

www.turkiyeklinikleri.com cannot reach to user’s identity, address, service providers or other information. The users may send this information to the website through forms if they would like to. However, www.turkiyeklinikleri.com may collect your hardware and software information. The information consists of your IP address, browser type, operating system, domain name, access time, and related websites. www.turkiyeklinikleri.com cannot sell the provided user information (your name, e-mail address, home and work address, phone number) to the third parties, publish it publicly, or keep it in the website. Gathered information has a directing feature to be a source for the website’s visitor profile, reporting and promotion of the services.

www.turkiyeklinikleri.com uses the taken information:

-To enhance, improve and maintain the quality of the website

-To generate visitor’s profile and statistical data

-To determine the tendency of the visitors on using our website

-To send print publications/correspondences

-To send press releases or notifications through e-mail

-To generate a list for an event or competition

By using www.turkiyeklinikleri.com you are considered to agree that;

-Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. cannot be hold responsible for any user’s illegal and immoral behavior,

-Terms of use may change from time to time,

-It is not responsible for other websites’ contents it cannot control or the harms they may cause although it uses the connection they provided.

Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. may block the website to users in the following events:

-Information with wrong, incomplete, deceiving or immoral expressions is recorded to the website,

-Proclamation, advertisement, announcement, libelous expressions are used against natural person or legal identity,

-During various attacks to the website,

-Disruption of the website because of a virus.

Written, visual and audible materials of the website, including the code and the software are under protection by legal legislation.

Without the written consent of Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. the information on the website cannot be downloaded, changed, reproduced, copied, republished, posted or distributed.

All rights of the software and the design of the website belong to Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc.

Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. will be pleased to hear your comments about our terms of use. Please share the subjects you think may enrich our website or if there is any problem regarding our website.

info@turkiyeklinikleri.com